Nanoemulsion of myricetin enhances its anti-tumor activity in nude mice of triple-negative breast cancer xenografts
Frontiers in Oncology · 09.06.2025 · 15
DOI: 10.3389/fonc.2025.1563076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 09.06.2025. Verfasst von Preeti Sharma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard University, Delhi, India. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Myricetin, a naturally occurring flavonoid exhibits good anti-cancer properties. However, its practical application is limited due to poor aqueous solubility and low bioavailability. To overcome these challenges, a nanoemulsion-based formulation of myricetin was developed and its anti-tumor efficacy was compared with Myricetin alone in TNBC xenografts.
Methods
Athymic nude mice were randomly divided into three groups (n=8) of control, Myricetin (50mg/kg), Myr-NE (25mg/kg), and subcutaneously implanted with MDA-MB-231 cells. After the 7-day treatment regimen, tumor volume was measured for up to 21 days, followed by mechanistic investigation, including tumor histology and immunoblotting. Tumor migration, invasion, cell proliferation kinetics, clonogenic, oxidative stress, and nuclear fragmentation studies were performed in tumor-derived cells. ANOVA test was further performed for statistical analysis to assess the significance between the experimental groups.
Results
Myr-NE treatment substantially reduced tumor progression compared to Myricetin alone in TNBC xenografts. The invasion, proliferation, and clonogenicity of Myr-NE tumor-derived cells were significantly reduced compared to Myricetin. The mechanistic investigation revealed that Myr-NE treatment effectively inhibits the PI3K/AKT/mTOR signaling and VEGFR2, accompanied by a significant reduction in the level of tumorigenic factors, including HIF-1α, Ki67, and MMP9 proteins compared to Myricetin. Myr-NE treatment also showed increased oxidative stress and DNA damage, resulting in enhanced tumor cell death compared to Myricetin alone.
Conclusion
Similar to our earlier observation in in-vitro TNBC model, findings in the present study highlights that nanoemulsion of myricetin potentiates its anti-tumor activity in TNBC xenografts and provide a promising drug delivery strategy for better clinical outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard University, Delhi, India.
- Division-Radiological Imaging and Neurocognition, Radiopharmaceutical Chemistry Laboratory, Institute of Nuclear Medicine and Allied Sciences (INMAS), Defence Research and Development Organisation (DRDO), Timarpur, Delh…
- Radiation and Cell Signaling Research, Institute of Nuclear Medicine and Allied Sciences (INMAS), Defence Research and Development Organisation (DRDO), Timarpur, Delhi, India.
- Department of Chemistry, Indian Institute of Technology (IIT), Roorkee, Roorkee-Uttarakhand, India.
Zitieren
APA
Sharma, P., Rai, Y., Khan, M. A., Bhatt, A. N., Najmi, A. K., Chaturvedi, S., Akhtar, M., & Mishra, A. K. (2025). Nanoemulsion of myricetin enhances its anti-tumor activity in nude mice of triple-negative breast cancer xenografts. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1563076
Vancouver
Sharma P, Rai Y, Khan MA, Bhatt AN, Najmi AK, Chaturvedi S, et al. Nanoemulsion of myricetin enhances its anti-tumor activity in nude mice of triple-negative breast cancer xenografts. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1563076
BibTeX
@article{Sharma2025,
author = {Sharma, Preeti and Rai, Yogesh and Khan, Mohammad Ahmed and Bhatt, Anant Narayan and Najmi, Abul Kalam and Chaturvedi, Shubhra and Akhtar, Mohd and Mishra, Anil Kumar},
title = {Nanoemulsion of myricetin enhances its anti-tumor activity in nude mice of triple-negative breast cancer xenografts},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1563076}
}
EUVIMED